AIM: To assess the translation of pharmacokinetic-pharmacodynamic (PK-PD) relationships for heart rate effects of PF-00821385 in dog and man. METHODS: Cardiovascular telemetric parameters and concentration data were available for animals receiving active doses (0.5-120 mg kg(-1), n= 4) or vehicle. PF-00821385 was administered to 24 volunteers and pharmacokinetic and vital signs data were collected. PK-PD models were fitted using nonlinear mixed effects. RESULTS: Compartmental models with linear absorption and clearance were used to describe pharmacokinetic disposition in animal and man. Diurnal variation in heart and pulse rate was best described with a single cosine function in both dog and man. Canine and human heart rate change were described by a linear model with free drug slope 1.76 bpm microM(-1)[95% confidence interval (CI) 1.17, 2.35] in the dog and 0.76 bpm microM(-1) (95% CI 0.54, 1.14) in man. CONCLUSIONS: The preclinical translational of concentration-response has been described and the potential for further interspecies extrapolation and optimization of clinical trial design is addressed.
RCT Entities:
AIM: To assess the translation of pharmacokinetic-pharmacodynamic (PK-PD) relationships for heart rate effects of PF-00821385 in dog and man. METHODS: Cardiovascular telemetric parameters and concentration data were available for animals receiving active doses (0.5-120 mg kg(-1), n= 4) or vehicle. PF-00821385 was administered to 24 volunteers and pharmacokinetic and vital signs data were collected. PK-PD models were fitted using nonlinear mixed effects. RESULTS: Compartmental models with linear absorption and clearance were used to describe pharmacokinetic disposition in animal and man. Diurnal variation in heart and pulse rate was best described with a single cosine function in both dog and man. Canine and human heart rate change were described by a linear model with free drug slope 1.76 bpm microM(-1)[95% confidence interval (CI) 1.17, 2.35] in the dog and 0.76 bpm microM(-1) (95% CI 0.54, 1.14) in man. CONCLUSIONS: The preclinical translational of concentration-response has been described and the potential for further interspecies extrapolation and optimization of clinical trial design is addressed.
Authors: Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl Journal: Trends Pharmacol Sci Date: 2008-03-18 Impact factor: 14.819
Authors: T G Hammond; L Carlsson; A S Davis; W G Lynch; I MacKenzie; W S Redfern; A T Sullivan; A J Camm Journal: Cardiovasc Res Date: 2001-03 Impact factor: 10.787
Authors: B J Dezube; T A Dahl; T K Wong; B Chapman; M Ono; N Yamaguchi; S D Gillies; L B Chen; C S Crumpacker Journal: J Infect Dis Date: 2000-07-28 Impact factor: 5.226
Authors: Reuben Howden; Eric Liu; Laura Miller-DeGraff; Heather L Keener; Christopher Walker; James A Clark; Page H Myers; D Clay Rouse; Tim Wiltshire; Steven R Kleeberger Journal: Am J Physiol Heart Circ Physiol Date: 2008-05-02 Impact factor: 4.733
Authors: Neil Benson; Joost de Jongh; Jonathan D Duckworth; Hannah M Jones; Henry E Pertinez; Jaiessh K Rawal; Tamara J van Steeg; Piet H Van der Graaf Journal: Antimicrob Agents Chemother Date: 2009-12-22 Impact factor: 5.191
Authors: T A Collins; L Bergenholm; T Abdulla; Jwt Yates; N Evans; M J Chappell; J T Mettetal Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-03-11